Compare Abeona Therapeutics Inc (ABEO) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Anheuser-Busch Inbev SA — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 377.5× Abeona Therapeutics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BUD | |
|---|---|---|
Market Cap | $421.19M | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $86.48 |
52-Week Low | $4.17 | $57.93 |
Enterprise Value | $276.10M | $223.42B |
Dividend Yield | — | 1.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
